ARS Pharmaceuticals Inc
SPRY
Get informed when a big investor buys or sells
+ FollowMarket Cap$848.05M
Close$
$-6.07
170.9% downside
Current Fair Value
170.9% downsideOvervalued by 170.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $848.05 Million |
|---|---|
| Enterprise Value | $823.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.74 |
| Beta | 0.83 |
| Outstanding Shares | 99,296,408 |
Return
| Return on Equity | -322.92% |
|---|---|
| Return on Assets | -68.84% |
| Return on Invested Capital | -83.06% |
Valuation & Multiples
| P/E Ratio | -4.25 |
|---|---|
| PEG | -5.41 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.32 |
| Enterprise Value to EBIT | -4.17 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$22.20 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$31.54 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2903▼ 62.94% |
|---|---|
| Total Calls | 226,000▼ 29.88% |
| Total Puts | 65,600▼ 77.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.89%▲ 4.83% |
|---|---|
| Total Invested | $752.89M▼ 27.36% |
| Investors Holding | 206▲ 10.00% |
ESG Score
No data
About ARS Pharmaceuticals Inc
54 employeesSilverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administe...